Posted:
Neuromod Devices announced that Lenire, a bimodal neuromodulation device for tinnitus, is now available in Canada through 21 clinics across Ontario, British Columbia, Alberta, Manitoba, and Quebec. The launch follows Health Canada authorization received in late 2025.
Lenire delivers audio tones through Bluetooth headphones while simultaneously applying mild electrical pulses to the surface of the tongue. According to the company, patients typically use it at home for two 30-minute sessions per day over approximately 12 weeks under audiologist supervision. The device received FDA De Novo approval in the U.S. in 2023.
The company cites a Canadian Health Measures Survey indicating that 43% of Canadians report experiencing tinnitus in their lifetime. Neuromod also cites outcome data from two clinical trials and retrospective real-world patient analyses at independent U.S. clinics. These are company-reported figures; the real-world data comes from chart reviews at individual practices rather than randomized controlled trials. Prospective patients should discuss clinical evidence and suitability with a qualified audiologist.
Learn more here.
